|
adult add and alzheimerssp here is the NeuroTalk Communities,/p> You are currently viewing our boards as a guest which gives you limited access to view most discussions and our additional features. By joining our free community you will have accessibility to post topics, Communicate privately with fellow members (pm hours), answer customer polls, Upload content and access the special features. registration mark is fast, Simple and for no extra money so please, Join our open public today,/p> With the creation of ARICEPT (Donepezil) In aug of 1997, A new era began in the management of Alzheimer disease (text ad) In quebec. Until that point, No specific therapy was available to help remedy the devastating impact of AD on patients and their caregivers. The first of its new class of medication known as cholinesterase inhibitors, ARICEPT is indicated for New Era cappelli online the symptomatic therapy for mild to moderate AD,/p> on the market now, ARICEPT is the top prescribed AD medication in the world with a total of over 717 million patient days of use. In ontario, It remains the standard of care in the treating of mild to moderate Alzheimer disease and the total number of days of treatment with ARICEPT has reached more than 34 million,/p> Eight years of Studies ARICEPT has been the subject of studies for over eight years and has been assessed among a population of over 7,800 AD patients globally. Many of the international studies involved Canadian researchers and centres. to this point, few 1,200 Canadian AD patients took part in such clinical trials,/p> ARICEPT is the only health professional prescribed drug of its class with cumulative published trial data for up to almost five years; Patients in some of the clinical trials have been followed in excess of five years. It is also the only approved AD doctor prescribed drug with published data on safety in long term use in two (2) Oneyear placebocontrolled studies1,2 showing that its clinical benefits in terms of global function, Cognition and activities of daily living are sustained over time and that it is well New Era keps tolerated by patients in longterm treatment,/p> Data from three openlabel trials with the inclusion of a 98week openlabel extension study with 133 patients3, A 144week openlabel extension study with 763 patients with mild to moderate AD4 and a 152week openlabel study5 with 579 patients indicated that patients handled benefit with longterm use as measured by function and cognition,/p> A Success story for daily life Has not only been  shown to slow the advancement of AD patients symptoms, It can delay their need for transfer to institutional care, promises Dr. Serge Gauthier, McGill Centre of studies up to now in Aging, Montreal, quebec. Has also had an impact on symptoms such as cognition and everyday function for periods of up to three years. That is where the success story lies New Era keps and it is certainly a great contribution to improving quality of life for the patients, Their care providers and families, He really adds,/p> Science behind Canadian stipulations Was one of the first countries in the world to have clinical practice guidelines for managing AD, evokes Dr. Gauthier. Data presented the basis of evidence that helped the Canadian Consensus Conference on Dementia develop its tips for family physicians in 1998. The testimonials and referrals published in the Canadian Medical Association Journal 6, Included a trial course of ARICEPT to be prescribed to informed and willing patients with mild to moderate dementia due to probable AD,/p> Guidelines were key at the time and were certainly a key player in ensuring more consistent and improved care of persons with dementia by physicians across Canada,/p>
Related Articles -
New, Era, Italia,
|
